Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer - Scorecard - MDSpire

Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer

  • By

  • Giulia Sapuppo

  • Marco Russo

  • Grete Francesca Privitera

  • Michele Massimino

  • Sebastiano Piana

  • Maria Antonietta Trovato

  • Giusi Blanco

  • Davide Adinolfi

  • Giorgia Romano

  • Gabriella Pellegriti

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Tumor Location as a Distinct Prognostic Factor for Survival in Radioiodine-Refractory Thyroid Carcinoma

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with advanced thyroid carcinoma, particularly those with locoregional disease and distant metastases, should be clearly differentiated.
Care Setting

Key Highlights

  • highlight_3

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • i
      • m
      • a
      • g
      • i
      • n
      • g
      • m
      • o
      • d
      • a
      • l
      • i
      • t
      • i
      • e
      • s
      • s
      • u
      • c
      • h
      • a
      • s
      • C
      • T
      • o
      • r
      • M
      • R
      • I
      • f
      • o
      • r
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • .

      Risks

        Patient & Prescribing Data

        Provide additional outcomes data for the 43 patients treated.

        Clinical Best Practices

        • best_practice_2

        Related Resources & Content

        Original Source(s)

        Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer

        • by Giulia Sapuppo, Marco Russo, Grete Francesca Privitera, Michele Massimino, Sebastiano Piana, Maria Antonietta Trovato, Giusi Blanco, Davide Adinolfi, Giorgia Romano, Gabriella Pellegriti

        • June 11, 2026

        Related Content

        Construction and validation of a preoperative malignancy risk prediction model for ovarian-adnexal masses based on clinical and ultrasonographic features

        Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition

        Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer